The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Open accessAbstract
BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated cardiac arrest. The median follow-up was 5.6 years. RESULTS: The overall mean low-density lipoprotein cholesterol level was 26.5% lower in the rosuvastatin group than in the placebo group. The first coprimary outcome occurred in 235 participants (3.7%) in the rosuvastatin group and in 304 participants (4.8%) in the placebo group (hazard ratio, 0.76; 95% confidence interval [CI], 0.64 to 0.91; P=0.002). The results for the second coprimary outcome were consistent with the results for the first (occurring in 277 participants [4.4%] in the rosuvastatin group and in 363 participants [5.7%] in the placebo group; hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P<0.001). The results were also consistent in subgroups defined according to cardiovascular risk at baseline, lipid level, C-reactive protein level, blood pressure, and race or ethnic group. In the rosuvastatin group, there was no excess of diabetes or cancers, but there was an excess of cataract surgery (in 3.8% of the participants, vs. 3.1% in the placebo group; P=0.02) and muscle symptoms (in 5.8% of the participants, vs. 4.7% in the placebo group; P=0.005). CONCLUSIONS: Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; HOPE-3 ClinicalTrials.gov number, NCT00468923.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, there are three large, randomized trials of statin versus placebo where specific cognitive tests were performed, and no differences were seen between statin and placebo (166-169).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, there are three large, randomized trials of statin versus placebo where specific cognitive tests were performed, and no differences were seen between statin and placebo (160–163).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [163]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Heart Outcomes Prevention Evaluation 3 (HOPE-3), published in 2016, showed that low-dose statin therapy reduced the composite cardiovascular outcome by 24% but had no significant effect on mortality.19”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The effectiveness of statins for preventing the first occurrence and recurrence of stroke in Japanese populations was confirmed in a sub-analysis of the MEGA study620, 621) and in the JELIS study622).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [621]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Self-citationForouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., Bhutta, Z. A., Biryukov, S., Brauer, M., Burnett, R., Cercy, K., Charlson, F. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31679-8 · Cited by 7,698
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
O'Donnell, M. J., Xavier, D., Liu, L., Zhang, H., Chin, S. L., Rao-Melacini, P., Rangarajan, S., Islam, S., Pais, P., McQueen, M. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60834-3 · Cited by 3,448
Self-citationCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Forouzanfar, M. H., Alexander, L., Anderson, H. R., Bachman, V. F., Biryukov, S., Brauer, M., Burnett, R., Casey, D., Coates, M. M., Cohen, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00128-2 · Cited by 2,701
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Research works printed but not linked: 1
- Sackett DL, 2000, CMAJ, 162, 1311
Cited by
Sorted by citations
Items 801–847 of 847
ESTRATÉGIAS DE PREVENÇÃO DE DOENÇAS CARDIOVASCULARES
Lemos, P. N., Barbosa, G. B., Cunha, E. C. F., Moreira, T. G., & Teixeira, D. M. S. C. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i9.11204
Bempedoic Acid for Primary Prevention of Cardiovascular Events—Reply
Nissen, S. E., Nicholls, S. J., & Lincoff, A. M. (2023) · JAMA · doi:10.1001/jama.2023.17341
Is it time to recommend cardiovascular protection for all?
Greenstein, A. S., Reusch, J. E. B., & Heagerty, A. M. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003501
Tuquerres, D. A. C., Perez, P. N., Erazo, A. M. B., Figueroa, L., Fériz, K., & Casanova, M. (2023) · Interdisciplinary Journal of Epidemiology and Public Health · doi:10.18041/2665-427x/ijeph.2.9489
Polypill as a means of population pharmacological prevention of cardiovascular diseases
Lebedev, P. A., Петрухина, И. К., & Владимировна, П. Е. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-222-2-64-74
León, J. S. T., Ardila, L. J. P., Santamaria, M. J. C., Quintero, V. Q., Campo, E. R. Z., Corzo, M. J. O., Cantillo, F. A. A., Romero, L. D. J., Medina, R. A. A., Solano, M. J. C., et al. (2024) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v8i1.10179
Long-Term Mortality Prediction with Pooled Cohort Equations: Implications for Lipid-Lowering TherapyPreprint
Ma, Z., Moran, L. N., & Shirani, J. (2024) · medRxiv · doi:10.1101/2024.04.05.24305406
Kim, K., Ko, I., Kim, J., & Kim, D.-K. (2024) · Clinics and Practice · doi:10.3390/clinpract14040113 · Cited by 1
Cho, J. H., Cho, E. J., & Jeong, Y. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2024.0195
Low LDL-C: Is It all Good News?
Hartz, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01238-y
Ma, Z., Moran, L. N., & Shirani, J. (2024) · Cureus · doi:10.7759/cureus.72856
Sergey, S. V., Леонидовна, Б. С., Bychkova, O. I., Vlasov, D. S., Ledyaeva, A. A., Salasyuk, A. S., & Цома, В. В. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-307
Pavlović, J., Kavousi, M., Ikram, M. K., Bos, D., Ikram, M. A., & Leening, M. J. G. (2024) · Circulation · doi:10.1161/circulationaha.124.071071
Osataphan, S. A., Patell, R. D., Babuta, M., Rosovsky, R. P. G., Hisada, Y., Edmiston, C., Elavalakanar, P., Pfeffer, M., Bregar, A. J., Ramos, A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016107
Care pathway in patients after myocardial infarction in Denmark − healthcare and drug utilization
Flege, M. M., Kleinschmidt, T., Hansen, S., Jensen, K. J., Jensen, H. K., Christiansen, M. K., Merland, C. O., & Petersen, J. (2025) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101809
Park, J. H., Cho, K. H., Woo, S.-I., Rha, S., Cho, Y., Cha, K. S., Lim, H. E., Kim, W., Lee, N., Cho, S. W., et al. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.09.012
Cai, A., Cheng, Q., Zhou, D., Feng, X., Yan, M., Wu, S., Wang, J.-B., Nie, Z., & Feng, Y. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004143
Cardiovascular Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch17
Take an individualised approach with lipid-lowering therapy in the elderly
Zhuang-Yan, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01211-y
Zheng, X.-Z., Tang, L.-E., Xu, D., Xu, L.-Y., Zhao, Y.-L., Zhu, Y.-D., Lv, J.-C., & Yang, L. (2024) · Research Square · doi:10.21203/rs.3.rs-4027948/v1
Hsu, H.-Y., Lin, C.-J., Lee, Y.-S., Wu, T.-H., & Chien, K. (2020) · Figshare · doi:10.6084/m9.figshare.12650676
van der Ploeg, M. A., Poortvliet, R., Achterberg, W. P., Mooijaart, S. P., Gussekloo, J., & Drewes, Y. M. (2022) · Figshare · doi:10.6084/m9.figshare.19720057
van der Ploeg, M. A., Poortvliet, R., Achterberg, W. P., Mooijaart, S. P., Gussekloo, J., & Drewes, Y. M. (2022) · Figshare · doi:10.6084/m9.figshare.19720060
van der Ploeg, M. A., Poortvliet, R., Achterberg, W. P., Mooijaart, S. P., Gussekloo, J., & Drewes, Y. M. (2022) · Figshare · doi:10.6084/m9.figshare.19720054
Additional file 2 of Effect of alirocumab on cataracts in patients with acute coronary syndromes
Suc, G., Schwartz, G. G., Goodman, S. G., Jukema, J. W., Manvelian, G. Z., Poulouin, Y., Pordy, R. C., Scemama, M., Szarek, M. J., & Steg, P. G. (2023) · Figshare · doi:10.6084/m9.figshare.23536155
Additional file 1 of Effect of alirocumab on cataracts in patients with acute coronary syndromes
Suc, G., Schwartz, G. G., Goodman, S. G., Jukema, J. W., Manvelian, G. Z., Poulouin, Y., Pordy, R. C., Scemama, M., Szarek, M. J., & Steg, P. G. (2023) · Figshare · doi:10.6084/m9.figshare.23536152
Additional file 1 of The association of statin therapy and cancer: a meta-analysis
Chen, Z., Wu, P., Wang, J., Chen, P., Fang, Z., & Luo, F. (2023) · Figshare · doi:10.6084/m9.figshare.24547019
van der Ploeg, M. A., Poortvliet, R., Achterberg, W. P., Mooijaart, S. P., Gussekloo, J., & Drewes, Y. M. (2022) · Figshare · doi:10.6084/m9.figshare.19720063
Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity
Newman, C. B., Saunders, K. H., Schmitz, S. H., & Subramanian, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26712-3.00020-3
Challenges in achieving low-density lipoprotein targets: a cross-sectional study in statin users
Çiçekli, A., & Sağlan, Y. (2026) · Turkish Journal of Family Practice · doi:10.54308/turkjfampract.2026.888 · Cited by 1
Zhang, F., & Liao, Q. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1790509 · Cited by 1
Heilman, A. M., Warsavage, T. J., Liu, W. G., Wilson, P. W. F., Phillips, L. S., Reusch, J. E. B., & Raghavan, S. (2026) · medRxiv · doi:10.64898/2026.05.24.26354000
Luo, Z., Zhu, S., Lu, Y., Yili, W., & Xu, J. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1868003
EFFICACY VS EFFECTIVENESS OF STATIN IN PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE- META-ANALYSIS
Rajca, E., Giza, A., Marzec, U., Cyrkler, A., Cieślak, N., Dąbek, K., Paulina, G. I. Z. A., Wymoczył, K., Czyżak, K., & Chodkowska, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5093
Zhang, T., Li, D., Ning, Y., Shi, J., & Hu, Y. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/8814045
Плейотропні ефекти статинів: більше ніж просто зниження холестерину
Kanishcheva, O., Tselik, N. E., Lebedynska, M. M., & Shop, I. V. (2026) · Ukrainian Journal of Cardiology · doi:10.31928/2664-4479-2026.3.4656
Updates in management of cardiorenal syndrome
Chung, I., Chen, M., Anderson, L., & Banerjee, D. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001209
Li, H., Tian, H., Dong, H., Gao, H., Yang, B., Kou, S., & Tian, H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1845385
Ibrahim, E., Alaasmi, A., Mbionwu, U., Lastra, G., & Manrique‐Acevedo, C. (2026) · Physiology in health and disease · doi:10.1007/978-3-032-26472-5_9
South Asian Cardiovascular Risk
Kalra, D. K., Vedamurthy, D., Hosadurg, N., Goyal, A., Gupta, M., Pagidipati, N., Slipczuk, L. N., Dey, D., Mehta, A., Joshi, P., et al. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.07.007
Indian Guidelines on Hypertension (I.G.H.)-V. 2025–2026
Mehta, N., Mathur, G., Pal, J., Taneja, A., Wander, G. S., Pareek, K. K., Narsimulu, G., Saxena, P., Muruganathan, A., Chattetjee, N., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1495
Arnold, M. J., Spacek, L., Bush, K. N. V., Waring, A. A., Ballard‐Hernandez, J., Beckman, D., Kelley, C., Natarajan, S., Neubauer, B. E., Phillips, E. M., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-01374
Xue, Q., Wang, F., Zhang, Y., & Chen, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1867316
Selecting the optimal study design!
Albabtain, M. A., AlRasheed, M. M., Arafat, A. A., Breitinger, H., Breitinger, U., Elsisi, G. H., Gaber, A., Gumaa, M., Hozien, M., Abdelghany, R. M., et al. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45595-7.00015-7
Weekly Journal Scan: STAR(EE)ing beyond age: what statins can—and cannot—prevent after 70
Liuzzo, G., & Patrono, C. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag812
Diretriz Brasileira de Cardiogeriatria – 2026
Helber, I., Zanon, J. C. D. C., Peixoto, J. M., Caixeta, A. M., Nussbacher, A., de Oliveira, D. C., de Freitas, E. V., Cintra, F. D., Garcia, J. S., Miranda, R. D., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260795
Mansour, M. A., Hussein, M. E. I., & Foda, M. S. A.-D. T. (2026) · Next research. · doi:10.1016/j.nexres.2026.102631
Metadata
- Authors
- Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., Avezum, A., Piegas, L. S., Parkhomenko, A., Keltai, K., Keltai, M., Sliwa, K., Peters, R. J. G., Held, C., Chazova, I., Yusoff, K., Lewis, B. S., Jansky, P., Khunti, K., Toff, W. D., Reid, C. M., Varigos, J., Sanchez-Vallejo, G., McKelvie, R., Pogue, J., Jung, H., Gao, P., Diaz, R., & Lonn, E.
- Affiliations
- St. Michael's Hospital (CA)
- Semmelweis University (HU)
- Uppsala University (SE)
- ORCID
- Yusuf, Salim
- Bosch, Jackie
- Dagenais, Gilles
- Zhu, Jun
- Xavier, Denis
- Liu, Lisheng
- Pais, Prem
- López-Jaramillo, Patricio
- Leiter, Lawrence A.
- Piegas, Leopoldo S.
- Parkhomenko, Alexander
- Keltai, Katalin
- Sliwa, Karen
- Peters, Ron J.G.
- Held, Claes
- Chazova, Irina
- Yusoff, Khalid
- Lewis, Basil S.
- Khunti, Kamlesh
- Toff, William D.
- Reid, Christopher M.
- McKelvie, Robert
- Jung, Hyejung
- Lonn, Eva
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-05-26
- Volume
- 374
- Issue
- 21
- Pages
- 2021-2031
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2313998826
- Cited by
- 848
- References
- 23
- Citations by year
- 2026: 32 · 2025: 52 · 2024: 61 · 2023: 66 · 2022: 84 · 2021: 90 · 2020: 75 · 2019: 109 · 2018: 101 · 2017: 97 · 2016: 78
- FWCI
- 142.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Canadian Institutes of Health Research (IR2-91038))
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- rosuvastatin, statins, cholesterol lowering, intermediate cardiovascular risk, primary prevention, cardiovascular events, LDL cholesterol, ethnic diversity, C-reactive protein, cataract surgery, statin adverse effects, muscle symptoms, diabetes risk, cardiovascular mortality, myocardial infarction, stroke, heart failure, revascularization, cardiac arrest, cardiovascular risk stratification, lipid-lowering therapy
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
